Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure.

Trial Profile

Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Hydroxycarbamide (Primary)
  • Indications Sickle cell anaemia
  • Focus Pharmacokinetics
  • Acronyms DARH
  • Sponsors addmedica
  • Most Recent Events

    • 23 Jan 2017 Status changed from recruiting to completed.
    • 23 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 23 Mar 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top